In this regard, therapeutic upregulation of C/EBPα with small activating RNA (saRNA; MTL-CEBPA) has been tested in the preclinical and clinical setting in combination with sorafenib (NCT02716012), resulting in an overall reduction in pro-tumour M2 TAMs and showing anti-tumour responses in patients with advanced HCC. Here, CEBPA is linked to hepatocellular carcinoma.